{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:08:04Z","timestamp":1788984484619,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16H0503302, 18F18399, 18H02337"],"award-info":[{"award-number":["16H0503302, 18F18399, 18H02337"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19KK0174"],"award-info":[{"award-number":["19KK0174"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Babesiosis represents a veterinary and medical threat, with a need for novel drugs. Artemisinin-based combination therapies (ACT) have been successfully implemented for malaria, a human disease caused by related parasites, <jats:italic>Plasmodium<\/jats:italic> spp. The aim of this study was to investigate whether ACT is active against <jats:italic>Babesia in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Mefloquine, tafenoquine, primaquine, methylene blue and lumefantrine, alone or in combination with artesunate, were tested <jats:italic>in vitro<\/jats:italic> against <jats:italic>Babesia bovis<\/jats:italic>. Parasite growth was verified using a SYBR green I-based fluorescence assay. Mice infected with <jats:italic>Babesia microti<\/jats:italic> were treated with mefloquine or tafenoquine, alone or in combination with artesunate, and parasitemia was verified by microscopy and PCR.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>All drugs, except lumefantrine, showed <jats:italic>in vitro<\/jats:italic> activity against <jats:italic>B<\/jats:italic>. <jats:italic>bovis<\/jats:italic>, with methylene blue showing the most potent activity (concentration 0.2 \u03bcM). Combination with artesunate led to improved activity, with mefloquine showing a striking 20-fold increase in activity. Tafenoquine (10 mg\/kg, base), combined or not with artesunate, but not mefloquine, induced rapid clearance of <jats:italic>B<\/jats:italic>. <jats:italic>microti in vivo<\/jats:italic> by microscopy, but mice remained PCR-positive. Blood from mice treated with tafenoquine alone, but not with tafenoquine-artesunate, was infective for naive mice upon sub-inoculation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Tafenoquine, and most likely other 8-aminoquinoline compounds, are promising compounds for the development of ACT for babesiosis.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13071-020-04235-7","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T12:04:22Z","timestamp":1595246662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0133-6430","authenticated-orcid":false,"given":"Leonardo J. M.","family":"Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunduurem","family":"Tuvshintulga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arifin B.","family":"Nugraha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thillaiampalam","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoaki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"4235_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijpara.2018.09.005","volume":"49","author":"CD Keroack","year":"2019","unstructured":"Keroack CD, Elsworth B, Duraisingh MT. To kill a piroplasm: genetic technologies to advance drug discovery and target identification in Babesia. Int J Parasitol. 2019;49:153\u201363.","journal-title":"Int J Parasitol."},{"key":"4235_CR2","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.2174\/092986712799828355","volume":"19","author":"J Mosqueda","year":"2012","unstructured":"Mosqueda J, Olvera-Ramirez A, Aguilar-Tipacamu G, Canto GJ. Current advances in detection and treatment of babesiosis. Curr Med Chem. 2012;19:1504\u201318.","journal-title":"Curr Med Chem."},{"key":"4235_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijpara.2018.11.007","volume":"49","author":"PJ Krause","year":"2019","unstructured":"Krause PJ. Human babesiosis. Int J Parasitol. 2019;49:165\u201374.","journal-title":"Int J Parasitol."},{"key":"4235_CR4","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1056\/NEJM200011163432004","volume":"343","author":"PJ Krause","year":"2000","unstructured":"Krause PJ, Lepore T, Sikand VK, Gadbaw J Jr, Burke G, Telford SR 3rd, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med. 2000;343:1454\u20138.","journal-title":"N Engl J Med."},{"key":"4235_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/508667","volume":"43","author":"GP Wormser","year":"2006","unstructured":"Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089\u2013134.","journal-title":"Clin Infect Dis."},{"key":"4235_CR6","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1001\/jama.2016.2884","volume":"315","author":"E Sanchez","year":"2016","unstructured":"Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA. 2016;315:1767\u201377.","journal-title":"JAMA."},{"key":"4235_CR7","doi-asserted-by":"publisher","first-page":"e1005763","DOI":"10.1371\/journal.ppat.1005763","volume":"12","author":"WC Van Voorhis","year":"2016","unstructured":"Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, et al. Open source drug discovery with the malaria box compound collection for neglected diseases and beyond. PLoS Pathog. 2016;12:e1005763.","journal-title":"PLoS Pathog."},{"key":"4235_CR8","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.20151519","volume":"213","author":"LA Lawres","year":"2016","unstructured":"Lawres LA, Garg A, Kumar V, Bruzual I, Forquer IP, Renard I, et al. Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone. J Exp Med. 2016;213:1307\u201318.","journal-title":"J Exp Med."},{"key":"4235_CR9","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.1128\/AAC.00928-16","volume":"60","author":"AS Paul","year":"2016","unstructured":"Paul AS, Moreira CK, Elsworth B, Allred DR, Duraisingh MT. Extensive shared chemosensitivity between malaria and babesiosis blood-stage parasites. Antimicrob Agents Chemother. 2016;60:5059\u201363.","journal-title":"Antimicrob Agents Chemother."},{"key":"4235_CR10","first-page":"18","volume":"25","author":"B Tuvshintulga","year":"2015","unstructured":"Tuvshintulga B, Sivakumar T, Salama AA, Yokoyama N, Igarashi I. Evaluation of inhibitory effect of methylene blue against Babesia and Theileria parasites. J Protozool Res. 2015;25:18\u201328.","journal-title":"J Protozool Res."},{"key":"4235_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1128\/AAC.41.1.91","volume":"41","author":"SE Marley","year":"1997","unstructured":"Marley SE, Eberhard ML, Steurer FJ, Ellis WL, McGreevy PB, Ruebush TK 2nd. Evaluation of selected antiprotozoal drugs in the Babesia microti-hamster model. Antimicrob Agents Chemother. 1997;41:91\u20134.","journal-title":"Antimicrob Agents Chemother."},{"key":"4235_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/infdis\/jiz119","volume":"220","author":"DG Mordue","year":"2019","unstructured":"Mordue DG, Wormser GP. Could the drug tafenoquine revolutionize treatment of Babesia microti infection? J Infect Dis. 2019;220:442\u20137.","journal-title":"J Infect Dis."},{"key":"4235_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1128\/AAC.18.2.289","volume":"18","author":"TK Ruebush 2nd","year":"1980","unstructured":"Ruebush TK 2nd, Contacos PG, Steck EA. Chemotherapy of Babesia microti infections in Mongolian jirds. Antimicrob Agents Chemother. 1980;18:289\u201391.","journal-title":"Antimicrob Agents Chemother."},{"key":"4235_CR14","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3855\/jidc.5500","volume":"9","author":"JM Yao","year":"2015","unstructured":"Yao JM, Zhang HB, Liu CS, Tao Y, Yin M. Inhibitory effects of 19 antiprotozoal drugs and antibiotics on Babesia microti infection in BALB\/c mice. J Infect Dev Ctries. 2015;9:1004\u201310.","journal-title":"J Infect Dev Ctries."},{"key":"4235_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijpddr.2019.06.004","volume":"10","author":"AB Nugraha","year":"2019","unstructured":"Nugraha AB, Tuvshintulga B, Guswanto A, Tayebwa DS, Rizk MA, Gantuya S, et al. Screening the medicines for malaria venture pathogen box against piroplasm parasites. Int J Parasitol Drugs Drug Resist. 2019;10:84\u201390.","journal-title":"Int J Parasitol Drugs Drug Resist."},{"key":"4235_CR16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1128\/AAC.47.2.800-803.2003","volume":"47","author":"A Nagai","year":"2003","unstructured":"Nagai A, Yokoyama N, Matsuo T, Bork S, Hirata H, Xuan X, et al. Growth-inhibitory effects of artesunate, pyrimethamine, and pamaquine against Babesia equi and Babesia caballi in in vitro cultures. Antimicrob Agents Chemother. 2003;47:800\u20133.","journal-title":"Antimicrob Agents Chemother."},{"key":"4235_CR17","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1292\/jvms.65.1171","volume":"65","author":"S Kumar","year":"2003","unstructured":"Kumar S, Gupta AK, Pal Y, Dwivedi SK. In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys. J Vet Med Sci. 2003;65:1171\u20137.","journal-title":"J Vet Med Sci."},{"key":"4235_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.parint.2010.06.004","volume":"59","author":"YK Goo","year":"2010","unstructured":"Goo YK, Terkawi MA, Jia H, Aboge GO, Ooka H, Nelson B, et al. Artesunate, a potential drug for treatment of Babesia infection. Parasitol Int. 2010;59:481\u20136.","journal-title":"Parasitol Int."},{"key":"4235_CR19","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.exppara.2013.10.006","volume":"135","author":"ML Mazuz","year":"2013","unstructured":"Mazuz ML, Golenser J, Fish L, Haynes RK, Wollkomirsky R, Leibovich B, Shkap V. Artemisone inhibits in vitro and in vivo propagation of Babesia bovis and B. bigemina parasites. Exp Parasitol. 2013;135:690\u20134.","journal-title":"Exp Parasitol."},{"key":"4235_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.parint.2014.12.006","volume":"64","author":"A Iguchi","year":"2015","unstructured":"Iguchi A, Matsuu A, Matsuyama K, Hikasa Y. The efficacy of artemisinin, artemether, and lumefantrine against Babesia gibsoni in vitro. Parasitol Int. 2015;64:190\u20133.","journal-title":"Parasitol Int."},{"key":"4235_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.phrs.2016.11.012","volume":"117","author":"CS Loo","year":"2017","unstructured":"Loo CS, Lam NS, Yu D, Su XZ, Lu F. Artemisinin and its derivatives in treating protozoan infections beyond malaria. Pharmacol Res. 2017;117:192\u2013217.","journal-title":"Pharmacol Res."},{"key":"4235_CR22","doi-asserted-by":"publisher","first-page":"101919","DOI":"10.1016\/j.parint.2019.04.016","volume":"74","author":"PG Mathenge","year":"2020","unstructured":"Mathenge PG, Low SK, Vuong NL, Mohamed MYF, Faraj HA, Alieldin GI, et al. Efficacy and resistance of different artemisinin-based combination therapies: a systematic review and network meta-analysis. Parasitol Int. 2020;74:101919.","journal-title":"Parasitol Int."},{"key":"4235_CR23","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4269\/ajtmh.2003.68.334","volume":"68","author":"S Bork","year":"2003","unstructured":"Bork S, Yokoyama N, Matsuo T, Claveria FG, Fujisaki K, Igarashi I. Growth inhibitory effect of triclosan on equine and bovine Babesia parasites. Am J Trop Med Hyg. 2003;68:334\u201340.","journal-title":"Am J Trop Med Hyg."},{"key":"4235_CR24","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1128\/AAC.00022-14","volume":"58","author":"A Guswanto","year":"2014","unstructured":"Guswanto A, Sivakumar T, Rizk MA, Elsayed SA, Youssef MA, El Said Eel S, et al. Evaluation of a fluorescence-based method for antibabesial drug screening. Antimicrob Agents Chemother. 2014;58:4713\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"4235_CR25","doi-asserted-by":"publisher","first-page":"e0125276","DOI":"10.1371\/journal.pone.0125276","volume":"10","author":"MA Rizk","year":"2015","unstructured":"Rizk MA, El-Sayed SA, Terkawi MA, Youssef MA, El Said el Sel S, Elsayed G, et al. Optimization of a fluorescence-based assay for large-scale drug screening against Babesia and Theileria parasites. PLoS ONE. 2015;10:e0125276.","journal-title":"PLoS ONE."},{"key":"4235_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/pst.426","volume":"10","author":"JL Sebaugh","year":"2011","unstructured":"Sebaugh JL. Guidelines for accurate EC50\/IC50 estimation. Pharm Stat. 2011;10:128\u201334.","journal-title":"Pharm Stat."},{"key":"4235_CR27","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1128\/IAI.67.8.4143-4148.1999","volume":"67","author":"I Igarashi","year":"1999","unstructured":"Igarashi I, Suzuki R, Waki S, Tagawa Y, Seng S, Tum S, et al. Roles of CD4(+) T cells and gamma interferon in protective immunity against Babesia microti infection in mice. Infect Immun. 1999;67:4143\u20138.","journal-title":"Infect Immun."},{"key":"4235_CR28","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1128\/AAC.01614-15","volume":"60","author":"B Tuvshintulga","year":"2016","unstructured":"Tuvshintulga B, AbouLaila M, Davaasuren B, Ishiyama A, Sivakumar T, Yokoyama N, et al. Clofazimine inhibits the growth of Babesia and Theileria parasites in vitro and in vivo. Antimicrob Agents Chemother. 2016;60:2739\u201346.","journal-title":"Antimicrob Agents Chemother."},{"key":"4235_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa195","author":"B Tuvshintulga","year":"2020","unstructured":"Tuvshintulga B, Vannier E, Tayebwa DS, Gantuya S, Sivakumar T, Guswanto A, et al. Clofazimine, a promising drug for the treatment of Babesia microti infection in severely immunocompromised hosts. J Infect Dis. 2020. https:\/\/doi.org\/10.1093\/infdis\/jiaa195.","journal-title":"J Infect Dis."},{"key":"4235_CR30","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1128\/JCM.30.8.2097-2103.1992","volume":"30","author":"DH Persing","year":"1992","unstructured":"Persing DH, Mathiesen D, Marshall WF, Telford SR, Spielman A, Thomford JW, Conrad PA. Detection of Babesia microti by polymerase chain reaction. J Clin Microbiol. 1992;30:2097\u2013103.","journal-title":"J Clin Microbiol."},{"key":"4235_CR31","first-page":"34","volume":"36","author":"L Chanthap","year":"2005","unstructured":"Chanthap L, Tsuyuoka R, Na-Bangchang K, Nivanna N, Suksom D, Sovannarith T, Socheat D. Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine. Southeast Asian J Trop Med Public Health. 2005;36:34\u201343.","journal-title":"Southeast Asian J Trop Med Public Health."},{"key":"4235_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.","journal-title":"Malar J."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04235-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-020-04235-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04235-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T23:09:53Z","timestamp":1626736193000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-020-04235-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4235"],"URL":"https:\/\/doi.org\/10.1186\/s13071-020-04235-7","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"3 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All protocols were approved by the Obihiro University ethical committee on animal experimentation (approval number: 19-105).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"362"}}